menu
    • menu
    [{"orgOrder":0,"company":"Midas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFR A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Midas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Midas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Midas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Midas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Midas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Midas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Midas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Midas Pharma","sponsor":"Pharmacare Premium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"MALTA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pazopanib Hydrochloride","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Midas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Midas Pharma \/ Midas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Midas Pharma \/ Midas Pharma"},{"orgOrder":0,"company":"Midas Pharma","sponsor":"Apontis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Bisoprolol Fumarate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Midas Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Midas Pharma \/ Midas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Midas Pharma \/ Midas Pharma"},{"orgOrder":0,"company":"Midas Pharma","sponsor":"Apontis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Candesartan Cilexetil","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Midas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Midas Pharma \/ Midas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Midas Pharma \/ Midas Pharma"},{"orgOrder":0,"company":"Midas Pharma","sponsor":"Coripharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ICELAND","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Raltegravir Potassium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Midas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Midas Pharma \/ Midas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Midas Pharma \/ Midas Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Midas Pharma

    Menu

    Midas Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Midas Pharma

                            Germany
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothMidas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ranibizumab Launch - Midas Pharma is the Marketing Authorisation Holder (MAH) of a Biosimilar

                            Details : Ranivisio (ranibizumab) is a VEGF-A inhibitor, which is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and diabetic macular edema.

                            Brand Name : Ranivisio

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 11, 2023

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Midas Pharma

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Midas Pharma

                            Germany
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothMidas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

                            Lead Product(s) : Bisoprolol Fumarate,Amlodipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Recipient : Apontis Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Apontis Pharma and Midas Pharma Agree on Further Development Partnership for The Market Launch of A Single Pil...

                            Details : The aim of the partnership is the contract development of a Single Pill, Biramlo, with a combination of two leading active ingredients,bisoprolol fumarate and amlodipine for the treatment of high blood pressure (hypertension).

                            Brand Name : Biramlo

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 19, 2022

                            Lead Product(s) : Bisoprolol Fumarate,Amlodipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Recipient : Apontis Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            Midas Pharma

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Midas Pharma

                            Germany
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothMidas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EMA CHMP Recommends Grant of Marketing Authorization of Ranibizumab Biosimilar

                            Details : The active substance of Ranivisio is ranibizumab, a monoclonal antibody fragment (ATC code: S01LA04) which modulates angiogenesis by inhibiting vascular endothelial growth factor A. Ranivisio is a biosimilar medicinal product.

                            Brand Name : Ranivisio

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 23, 2022

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Midas Pharma

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Midas Pharma

                            Germany
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothMidas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

                            Lead Product(s) : Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Recipient : Apontis Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            APONTIS PHARMA and Midas Pharma Announce Development Partnership to Launch Single Pill with Pan-european Intel...

                            Details : The objective is the contract development of a Single Pill with a combination of three leading active ingredients, including candesartan cilexetil, amlodipine besylate and atorvastatin calcium trihydrate for the treatment of high blood pressure (hyperten...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 14, 2021

                            Lead Product(s) : Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Recipient : Apontis Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            Midas Pharma

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Midas Pharma

                            Germany
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothMidas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

                            Lead Product(s) : Pazopanib Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Pharmacare Premium

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Midas Pharma’s Partner, the Malta-based Generics Developer Pharmacare Premium, Has Successfully Conducted BE...

                            Details : Vorient-Generic (pazopanib) is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma & advanced soft tissue sarcoma who have received prior chemotherapy.

                            Brand Name : Vorient-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 26, 2021

                            Lead Product(s) : Pazopanib Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Pharmacare Premium

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Midas Pharma

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Midas Pharma

                            Germany
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothMidas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

                            Lead Product(s) : Raltegravir Potassium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Coripharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Coripharma and Midas Have Entered into an Exclusive Licensing Partnership

                            Details : Corifarma and Midas entered into an exclusive out-licensing cooperation for the European territory. The respective product, Raltegravir, can be launched in the EU in 2023 as a generic and is used in treatment of HIV/AIDS.

                            Brand Name : Raltegravir-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 23, 2020

                            Lead Product(s) : Raltegravir Potassium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Coripharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            Midas Pharma

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth